B1 lymphocytes and myeloid dendritic cells in lymphoid organs are preferential extratumoral sites of parvovirus minute virus of mice prototype strain expression.
Due to their oncolytic properties and apathogenicity, autonomous parvoviruses have attracted significant interest as possible anticancer agents. Recent preclinical studies provided evidence of the therapeutic potential of minute virus of mice prototype strain (MVMp) and its recombinant derivatives. In a murine model of hemangiosarcoma, positive therapeutic outcome correlated with high intratumoral expression of MVMp-encoded genes in tumors and lymphoid organs, especially in tumor-draining lymph nodes. The source and relevance of this extratumoral expression, which came as a surprise because of the known fibrotropism of MVMp, remained unclear. In the present study, we investigated (i) whether the observed expression pattern occurs in different tumor models, (ii) which cell population is targeted by the virus, and (iii) the immunological consequences of this infection. Significant MVMp gene expression was detected in lymphoid tissues from infected tumor-free as well as melanoma-, lymphoma-, and hemangiosarcoma-bearing mice. This expression was especially marked in lymph nodes draining virus-injected tumors. Fluorescent in situ hybridization analysis, multicolor fluorescence-activated cell sorting, and quantitative reverse transcription-PCR revealed that MVMp was expressed in rare subpopulations of CD11b (Mac1)-positive cells displaying CD11c+ (myeloid dendritic cells [MDC]) or CD45B (B220+ [B1 lymphocytes]) markers. Apart from the late deletion of cytotoxic memory cells (CD8+ CD44+ CD62L-), this infection did not lead to significant alteration of the immunological profile of cells populating lymphoid organs. However, subtle changes were detected in the production of specific proinflammatory cytokines in lymph nodes from virus-treated animals. Considering the role of B1 lymphocytes and MDC in cancer and immunological surveillance, the specific ability of these cell types to sustain parvovirus-driven gene expression may be exploited in gene therapy protocols.
Raykov
Zahari
Z
Department of Surgery, Medical School, University of Heidelberg, INF 116, 60120 Heidelberg, Germany.
Savelyeva
Larissa
L
Balboni
Ginette
G
Giese
Thomas
T
Rommelaere
Jean
J
Giese
Nathalia A
NA
D000818:Animals; D001402:B-Lymphocytes / Q000276:immunology / Q000821:virology*; D039481:CD11b Antigen / Q000032:analysis; D039521:CD11c Antigen / Q000032:analysis; D003713:Dendritic Cells / Q000276:immunology / Q000821:virology*; D005260:Female; D015870:Gene Expression; D005814:Genes, Viral; D006394:Hemangiosarcoma / Q000821:virology; D017493:Leukocyte Common Antigens / Q000032:analysis; D008198:Lymph Nodes / Q000276:immunology / Q000821:virology; D016131:Lymphocyte Subsets / Q000276:immunology; D008221:Lymphoid Tissue / Q000276:immunology / Q000821:virology*; D008223:Lymphoma / Q000821:virology; D008546:Melanoma, Experimental / Q000821:virology; D051379:Mice; D008915:Minute Virus of Mice / Q000235:genetics* / Q000254:growth & development; D010322:Parvoviridae Infections / Q000276:immunology / Q000821:virology*; D013154:Spleen / Q000276:immunology / Q000821:virology; D014158:Transcription, Genetic
D039481:CD11b Antigen; D039521:CD11c Antigen; D017493:Leukocyte Common Antigens
Cell Immunol. 2000 Jun 15;202(2):124-35
10896772
Hum Gene Ther. 1999 Jul 1;10(10):1619-32
10428207
Cancer Gene Ther. 2001 Dec;8(12):958-65
11781658
Cytokine Growth Factor Rev. 2002 Apr;13(2):95-109
11900986
Cancer Gene Ther. 2002 May;9(5):432-42
11961666
J Exp Med. 2002 May 20;195(10):1233-45
12021304
Annu Rev Immunol. 2003;21:841-94
12615894
Nat Med. 2003 May;9(5):562-7
12704383
Nat Rev Immunol. 2003 Aug;3(8):630-41
12974478
Eur J Immunol. 2004 Feb;34(2):558-64
14768061
J Virol. 1972 Oct;10(4):586-90
4673484
J Virol. 1983 Jun;46(3):937-43
6602221
J Virol. 1983 Jun;46(3):944-55
6602222
Nucleic Acids Res. 1985 May 24;13(10):3617-33
3855242
J Virol. 1986 Jul;59(1):8-13
3712557
J Virol. 1988 May;62(5):1713-22
3357208
J Exp Med. 1992 Jan 1;175(1):71-9
1730928
J Immunol. 1992 Feb 15;148(4):1280-5
1737940
J Virol. 1992 May;66(5):2821-8
1560527
J Virol. 1992 May;66(5):3118-24
1373202
J Virol. 1992 Jun;66(6):3415-23
1316457
Proc Natl Acad Sci U S A. 1993 Sep 15;90(18):8702-6
8378352
Eur J Immunol. 1993 Nov;23(11):2813-20
8223857
Oncogene. 1993 Dec;8(12):3353-8
8247537
J Virol. 1994 Mar;68(3):1397-406
8107203
Proc Natl Acad Sci U S A. 1994 Jul 19;91(15):7291-5
8041783
Immunol Invest. 1994 Aug;23(4-5):293-311
7525472
Lab Invest. 1995 Oct;73(4):511-20
7474923
Immunology. 1996 Mar;87(3):467-74
8778035
Ann N Y Acad Sci. 1996 Oct 31;795:158-67
8958926
J Leukoc Biol. 1997 Mar;61(3):246-57
9060447
Leukemia. 1997 Apr;11 Suppl 3:167-9
9209332
Int J Cancer. 1998 Feb 9;75(4):584-9
9466660
J Gene Med. 2001 Jul-Aug;3(4):326-37
11529662